Cargando…

Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report

INTRODUCTION: Animal studies have reported that treatment with angiotensin II receptor blockers reduced kidney sodium-dependent glucose cotransporter expression. We therefore hypothesized that patients with hypertension treated with an angiotensin II receptor blocker (candesartan) would probably hav...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okada, Shuichi, Shibusawa, Ryo, Tagaya, Yuko, Saito, Tsugumichi, Yamada, Eijiro, Shimoda, Yoko, Satoh, Tetsurou, Okada, Junichi, Yamada, Masanobu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302117/ https://www.ncbi.nlm.nih.gov/pubmed/25515334 http://dx.doi.org/10.1186/1752-1947-8-428

Ejemplares similares

Comparing the efficacy of apple peels and a sodium-glucose cotransporter 2 inhibitor (ipragliflozin) on interstitial glucose levels: A pilot case study
por: Okada, Junichi, et al.
Publicado: (2020)

Continuous or Transient High Level of Glucose Exposure Differentially Increases Coronary Artery Endothelial Cell Proliferation and Human Colon Cancer Cell Proliferation
por: Shimoda, Yoko, et al.
Publicado: (2017)

Effect of carbohydrate counting using bolus calculators on glycemic control in type 1 diabetes patients during continuous subcutaneous insulin infusion
por: Yamada, Eijiro, et al.
Publicado: (2017)

Differences in the effects of Kenyan, Tanzanian, and Ethiopian coffee intake on interstitial glucose levels measured by FreeStyle Libre: A pilot case study
por: Okada, Junichi, et al.
Publicado: (2020)

Lower Renal Threshold for Glucose Reabsorption in Type 1 Diabetes Mellitus (T1DM) May Explain the Smaller Contribution of SGLT2 Inhibitors to the Improvement of Plasma Glucose Control Compared with T2DM
por: Osaki, Aya, et al.
Publicado: (2019)

NR4A1 (Nur77) Mediates Thyrotropin-Releasing Hormone-Induced Stimulation of Transcription of the Thyrotropin β Gene: Analysis of TRH Knockout Mice
por: Nakajima, Yasuyo, et al.
Publicado: (2012)

Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity
por: Okada, Junichi, et al.
Publicado: (2020)

Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD
por: Takahashi, Hirokazu, et al.
Publicado: (2021)

Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling
por: Suga, Takayoshi, et al.
Publicado: (2020)

High Expression of Nucleobindin-2 Is Associated With Poor Prognosis in Gastric Cancer
por: Okada, Junichi, et al.
Publicado: (2021)

Long‐term efficacy of the sodium–glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome
por: Nagashima, Shuichi, et al.
Publicado: (2020)

Ipragliflozin/tozinameran: Diabetic ketoacidosis: 2 case reports
Publicado: (2022)

Syntaxin4 Interacting Protein (Synip) Binds Phosphatidylinositol (3,4,5) Triphosphate
por: Saito, Tsugumichi, et al.
Publicado: (2012)

FAM83G Is a Novel Inducer of Apoptosis
por: Okada, Junichi, et al.
Publicado: (2020)

Transcriptional Regulation of the Angptl8 Gene by Hepatocyte Nuclear Factor-1 in the Murine Liver
por: Watanabe, Takuya, et al.
Publicado: (2020)

Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice
por: Kamezaki, Michitsugu, et al.
Publicado: (2018)

A concise and practical stereoselective synthesis of ipragliflozin L-proline
por: Ma, Shuai, et al.
Publicado: (2017)

Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model
por: Morishita, Asahiro, et al.
Publicado: (2022)

Reply to: “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
por: van Kleef, Laurens A., et al.
Publicado: (2022)

Influence of the stage of emergency declaration due to the coronavirus disease 2019 outbreak on plasma glucose control of patients with diabetes mellitus in the Saku region of Japan
por: Watanabe, Takuya, et al.
Publicado: (2021)

Influence of Emergency Declaration Over Coronavirus Disease 2019 on Plasma Glucose Control of Patients With Diabetes Mellitus
por: Watanabe, Takuya, et al.
Publicado: (2021)

Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open‐label study (SOAR‐KOBE Study)
por: Miura, Hiroshi, et al.
Publicado: (2019)

Renal threshold for glucose reabsorption predicts diabetes improvement by sodium‐glucose cotransporter 2 inhibitor therapy
por: Osaki, Aya, et al.
Publicado: (2016)

Secreted Nucleobindin-2 Inhibits 3T3-L1 Adipocyte Differentiation
por: Tagaya, Yuko, et al.
Publicado: (2012)

Dapagliflozin rescues endoplasmic reticulum stress-mediated cell death
por: Shibusawa, Ryo, et al.
Publicado: (2019)

Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes
por: Kutoh, Eiji, et al.
Publicado: (2016)

Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease
por: Miyake, Teruki, et al.
Publicado: (2018)

Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice
por: Okuma, Hideyuki, et al.
Publicado: (2021)

Comparison of serum amylase level between dipeptidyl peptidase-4 inhibitor and GLP-1 analog administration in patients with type 2 diabetes mellitus
por: Okada, Junichi, et al.
Publicado: (2019)

Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice
por: Mori, Kentaro, et al.
Publicado: (2019)

Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor
por: Miyauchi, Masaaki, et al.
Publicado: (2017)

Reply to the Letter to the editor “Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD”
por: Takahashi, Hirokazu, et al.
Publicado: (2022)

Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus
por: Kawata, Takehiro, et al.
Publicado: (2017)

The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
por: Honda, Yasushi, et al.
Publicado: (2016)

Fyn phosphorylates AMPK to inhibit AMPK activity and AMP-dependent activation of autophagy
por: Yamada, Eijiro, et al.
Publicado: (2016)

A 52‐week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N‐ISM study
por: Kitazawa, Masaru, et al.
Publicado: (2021)

Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study
por: Iizuka, Takashi, et al.
Publicado: (2016)

Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial
por: Tanaka, Atsushi, et al.
Publicado: (2022)

Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high‐fat diet
por: Takagi, Susumu, et al.
Publicado: (2018)

Crosstalk between Thyroid Hormone Receptor and Liver X Receptor in the Regulation of Selective Alzheimer’s Disease Indicator-1 Gene Expression
por: Ishida, Emi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3re64nkoc86u80u58arhuis5ev